TNF and rheumatoid arthritis: As a second-line treatment, JAK-i is cost-effective than other csDMARDSs/bDMARDs for csDMARD-failed RA patients, but not cost-effective as a third line treatment for csDMARD-TNF-a-i failed RA patients.